XF
HRTX icon

XML Financial’s Heron Therapeutics HRTX Stock Holding History

XML Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$13K – 440
2025
Q4 		$13K Hold
10,000
– – ﹤0.01% 441
2025
Q3 		$12.6K Hold
10,000
– – ﹤0.01% 391
2025
Q2 		$20.7K Hold
10,000
– – ﹤0.01% 390
2025
Q1 		$22K Hold
10,000
– – ﹤0.01% 369
2024
Q4 		$15.3K Hold
10,000
– – ﹤0.01% 356
2024
Q3 		$19.9K Hold
10,000
– – ﹤0.01% 346
2024
Q2 		$35K Hold
10,000
– – ﹤0.01% 335
2024
Q1 		$27.7K Hold
10,000
– – ﹤0.01% 338
2023
Q4 		$17K Buy
+10,000
New +$11K ﹤0.01% 332

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

XML Financial's HRTX Position: Q1 2026 in Review

XML Financial sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $13K sold.

XML Financial first reported a position in HRTX in Q4 2023 and held it in 9 quarters. The position peaked at $35K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • XML Financial reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XML Financial sold 10,000 Heron Therapeutics shares in Q1 2026, an estimated $13K.
  • XML Financial first reported a position in Heron Therapeutics in Q4 2023 and held it in 9 quarters.
  • XML Financial's Heron Therapeutics position peaked at $35K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on XML Financial's 13F filing for Q1 2026, filed 16 Apr 2026.